Concurrent presence of high serum uric acid and inflammation is associated with increased incidence of type 2 diabetes mellitus in Korean adult population

Kyung Won Lee¹ & Dayeon Shin²

Although serum uric acid level and systemic inflammation have been highlighted as risk factors for type 2 diabetes mellitus (T2DM), little is known about these associations in the Korean population. Thus, we examined the individual and combined associations of serum uric acid and systemic inflammation (evaluated using high-sensitivity C-reactive protein [hs-CRP] measurement) with the future risk of T2DM. A total of 4152 Korean adults aged 45–76 years without T2DM, cancer, or gout at baseline in 2007–2008 from the Korean Genome and Epidemiology Study were followed up until 2016. Cox proportional hazard models were used to estimate the multivariable-adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) of T2DM according to sex-specific tertiles of serum uric acid and hs-CRP levels after adjustment for confounders. During the mean follow-up of 7.3 years, 548 participants developed T2DM. High serum uric acid and hs-CRP levels were independently associated with an increased incidence of T2DM. The multivariable-adjusted HRs (95% CIs) for the incidence of T2DM in the highest tertiles of serum uric acid and hs-CRP were 1.54 (1.24–1.93) and 1.90 (1.48–2.43), respectively. High levels of serum uric acid and hs-CRP in combination were associated with an increased incidence of T2DM (HR: 4.69; 95% CI: 2.81–7.84) compared to low levels of serum uric acid and hs-CRP. These findings suggest that the combination of high serum uric acid and hs-CRP levels was significantly associated with an elevated incidence of T2DM; however, their synergistic effects were not observed in middle-aged and elderly Korean adults.

With an increase in the burden of morbidity and premature mortality due to type 2 diabetes mellitus (T2DM), T2DM has become one of the greatest public health challenges. In 2017, the global prevalence of T2DM was 8.8% (425 million adults) among adults aged 20–79 years, and it is expected to increase to 9.9% (629 million adults) by 2045. Various complications resulting from T2DM, such as kidney diseases, retinopathy, foot damage, neuropathy, and cardiovascular diseases, are also significant problems; thus, prevention and proper management of T2DM, as well as the identification of effective biomarkers as early predictors of T2DM, are high-priority health issues.

C-reactive protein (CRP) is an acute reactant phase protein produced in the liver. The CRP level in the blood rapidly increases in response to inflammation; therefore, CRP is commonly used as a marker of systemic inflammation. Previous epidemiological studies found an association between the inflammation state (defined by CRP levels) and the risk of T2DM, and that CRP concentrations varied as to ethnicity. In addition to CRP, previous studies have reported that serum uric acid, which is the end-product of purine catabolism in humans, is positively associated with the risk of T2DM. Although the potential mechanisms of serum uric acid-induced T2DM remain unclear, elevated serum uric acid levels have been linked to endothelial dysfunction and oxidative stress, which in turn leads to insulin resistance and T2DM.

Previous cohort studies have indicated that high serum uric acid levels are positively associated with the levels of CRP and inflammatory cytokines, such as interleukin (IL)-1β, IL-6, and tumor necrosis factor (TNF)-α. Additionally, it has been hypothesized that serum uric acid may induce metabolic abnormalities through...
In addition, inflammatory cytokines increase the expression and activity of xanthine oxidase, an enzyme that catalyzes the conversion of uric acid precursors into uric acid. Therefore, we investigated the independent and interactive effects of serum uric acid level and inflammation on metabolic dysfunction. Although a few studies have evaluated the contributory effects of uric acid and inflammation on metabolic disorders, they were limited to cross-sectional and longitudinal studies with small sample sizes or short follow-up periods. Additional evidence based on prospective cohort studies with longer follow-up periods are needed to determine whether serum uric acid or inflammation is prospectively associated with T2DM risk and whether the concurrent presence of these two factors interacts synergistically to develop T2DM.

This study aimed to explore the independent role of uric acid and systemic inflammation (measured by high-sensitivity CRP [hs-CRP] levels) in predicting the future risk of T2DM. We also prospectively investigated the combined effects of serum uric acid and hs-CRP levels on the incidence of T2DM in a population-based cohort of middle-aged and elderly Korean adults.

**Results**

**Baseline characteristics.** During a mean follow-up period of 7.3 ± 1.6 years (30,365 total person-years), 548 new cases of T2DM were identified. The main characteristics of the study participants at baseline across the sex-specific tertiles of serum uric acid and hs-CRP levels are summarized in Table 1. Area of residence, education level, regular physical activity, body mass index (BMI), waist circumference (WC), diastolic blood pressure, triglycerides, total cholesterol, high-density lipoprotein (HDL)-cholesterol, and fasting blood glucose at baseline significantly differed according to tertiles of serum uric acid and hs-CRP levels (all, \( P < 0.05 \)). Participants in the highest tertile of serum uric acid levels (serum uric acid ranges 6.2 to 11.8 mg/dL for men; 4.5 to 10.6 mg/dL for women) were more likely to live in Ansan (rural area), drink more alcohol, exercise regularly, and have high BMI, WC, diastolic blood pressure, triglycerides, total cholesterol and fasting blood glucose levels and low HDL-cholesterol levels. Participants with the highest tertile of hs-CRP levels (hs-CRP ranges 1.05 to 9.82 mg/L for men; 0.90 to 9.88 mg/L for women) tended to be older, urban area (Ansan) residents, less educated, current smokers, less physically active, and have high BMI, WC, systolic and diastolic blood pressure, triglycerides, total cholesterol, and fasting blood glucose levels. Those from the highest tertile of serum uric acid or hs-CRP levels were more likely to have low HDL-cholesterol levels.

**Independent associations of serum uric acid and hs-CRP on incident T2DM risk.** The incidence rates, hazard ratios (HRs) and 95% confidence intervals (CIs) for T2DM are provided according to tertiles, continuous measures, and dichotomous categories of serum uric acid and hs-CRP levels in Tables 2 and 3. Participants in the highest tertile of serum uric acid had a 54% increased risk of T2DM compared to those in the lowest tertile after controlling for potential confounders (fully adjusted HR: 1.54; 95% CI: 1.24–1.93; \( P_{\text{trend}} < 0.0001 \)) (Table 2). Moreover, the fully adjusted HR was 1.47 (95% CI: 1.02–2.12) per 1 log mg/dL increase in serum uric acid levels. However, when we dichotomized serum uric acid levels (hyperuricemia vs. non-hyperuricemia), the associations were not significant (fully adjusted HR: 1.12; 95% CI: 0.87–1.44).

In the fully adjusted models, participants in the highest tertile of hs-CRP levels had an 90% increase in the risk of T2DM (fully adjusted HR: 1.90; 95% CI: 1.48–2.43; \( P_{\text{trend}} < 0.0001 \)) (Table 3). On a continuous basis, hs-CRP levels were also significantly associated with an increased incidence of T2DM (fully adjusted HR per 1 log mg/L increase: 1.17; 95% CI: 1.07–1.29). Similarly, participants with high inflammation (> 2 mg/L of hs-CRP) showed a 27% increased risk of T2DM (fully adjusted HR: 1.27; 95% CI: 1.02–1.57) than those with low inflammation (≤ 2 mg/L of hs-CRP).

**Combined associations of serum uric acid and hs-CRP on incident T2DM.** The associations between serum uric acid and hs-CRP levels and the incidence of T2DM are shown in Table 4. Although the test for the multiplicative interaction between serum uric acid and hs-CRP levels was not statistically significant (\( P_{\text{interaction}} = 0.3790 \)), when cross-classifying participants by both exposure variables, the risk of developing T2DM was the highest among participants with the combination of the highest tertile of serum uric acid and hs-CRP levels (HR: 4.69; 95% CI: 2.81–7.84) compared with the opposite extreme.

**Predicting incident T2DM with serum uric acid and hs-CRP.** A comparison of the performance of each model in predicting T2DM is presented in Table 5. The model with both serum uric acid and hs-CRP levels showed the best predictive accuracy, with an area under the receiver operating characteristic curve (AUC) between 0.731 and 0.930, and the highest Uno’s C-statistic (0.758) during the follow-up periods. C-statistics of the prediction models including at least one of the markers of serum uric acid and hs-CRP were significantly higher than those of the conventional model (all, \( P < 0.0001 \)). The predictive model including both serum uric acid and hs-CRP levels provided a better C-statistic than the model with only serum uric acid levels (\( P = 0.0030 \)) and higher than those of the conventional model (all, \( P < 0.0001 \)). The predictive model including both serum uric acid and hs-CRP levels provided a better C-statistic than the model with only serum uric acid levels (\( P = 0.0030 \)) and higher than those of the conventional model (all, \( P < 0.0001 \)).
serum uric acid, in combination with hs-CRP, exacerbated the future risk of developing T2DM, but these two factors did not act synergistically.

To the best of our knowledge, this is the first population-based cohort study to investigate the combined effects of serum uric acid and hs-CRP levels on the incidence of T2DM from a longitudinal perspective. Previous studies conducted in the United States and Europe have demonstrated positive associations between serum uric acid levels and the risk of T2DM. Data from the Framingham Heart Study and Rotterdam Study showed that elevated serum uric acid levels were significantly associated with an increased risk of T2DM. However, the role of serum uric acid level in T2DM development in Asian populations has not been consistent. A prospective study of Japanese men reported no association between serum uric acid levels and the incidence of T2DM. In contrast, a cohort study of 2,690 Chinese adults aged 35–97 years showed that the risk of T2DM was higher in individuals with the highest levels of serum uric acid than in those with the lowest levels (relative risk for Q5

| Tertile of uric acid1 | T1 (lowest) (n = 1382) | T2 (n = 1362) | T3 (highest) (n = 1408) | P  |
|----------------------|------------------------|--------------|-------------------------|----|
| Sex                  |                        | 0.4301       |                         |    |
| Men                  | 612 (44.3%)            | 660 (48.5%)  | 603 (42.8%)             |    |
| Women                | 770 (55.7%)            | 702 (51.5%)  | 805 (57.2%)             |    |
| Age (years)          | 57.2 ± 8.6             | 56.1 ± 8.3   | 57.1 ± 8.4              | 0.0759 |
| Area of residence    | < 0.0001               |              |                         |    |
| Ansan                | 786 (56.9)             | 675 (49.6)   | 682 (48.4)              |    |
| Ansung               | 596 (43.1)             | 687 (50.4)   | 726 (51.6)              |    |
| Education level      | 0.0296                 |              |                         |    |
| ≤ elementary school  | 450 (32.6%)            | 367 (26.9%)  | 429 (30.5%)             |    |
| Middle/high school   | 769 (55.6%)            | 783 (57.5%)  | 767 (54.5%)             |    |
| ≥ college            | 163 (11.8%)            | 212 (15.6%)  | 212 (15.0%)             |    |
| Smoking status       | 0.8038                 |              |                         |    |
| Never                | 927 (67.1)             | 872 (64.0%)  | 938 (66.6%)             |    |
| Past                 | 244 (17.6)             | 249 (18.3%)  | 251 (17.8%)             |    |
| Current              | 211 (15.3)             | 241 (17.7)   | 219 (15.6%)             |    |
| Alcohol consumption (grams/day) | 6.67 ± 16.7 | 8.2 ± 17.5 | 9.6 ± 20.7 | 0.0001 |
| Regular physical activity | 0.0178             |              |                         |    |
| Yes                  | 506 (36.6)             | 522 (38.3%)  | 577 (41.0%)             |    |
| No                   | 876 (63.4%)            | 840 (61.7%)  | 831 (59.0%)             |    |
| Body mass index (kg/m²) | 23.6 ± 2.9        | 24.3 ± 2.9   | 25.2 ± 3.0              |    |
| Waist circumference (cm) | 81.9 ± 9.2         | 83.4 ± 9.4   | 85.6 ± 9.7              |    |
| Systolic blood pressure (mmHg) | 116.7 ± 16.4    | 116.9 ± 16.0 | 117.9 ± 16.1            | 0.0964 |
| Diastolic blood pressure (mmHg) | 76.1 ± 9.5       | 77.1 ± 9.7   | 78.3 ± 9.9              |    |
| Triglycerides (mg/dL) | 132.9 ± 74.6       | 148.2 ± 97.8 | 168.9 ± 97.9            |    |
| Total cholesterol (mg/dL) | 183.7 ± 32.6     | 188.9 ± 33.6 | 193.8 ± 35.0            |    |
| HDL-cholesterol (mg/dL) | 45.9 ± 9.9        | 44.9 ± 9.8   | 44.2 ± 9.8              |    |
| Fasting blood glucose (mg/dL) | 90.7 ± 8.2       | 91.4 ± 8.9   | 92.3 ± 9.1              |    |
| Family history of diabetes | 0.3569           |              |                         |    |
| Yes                  | 22 (1.6)              | 25 (1.8)     | 29 (2.1)                |    |
| No                   | 1,360 (98.4)          | 1,337 (98.2) | 1,379 (97.9)            |    |

Table 1. Baseline characteristics of the study participants by tertile of serum uric acid and high-sensitivity C-reactive protein levels in Korean adults aged 45–76 years. T tertile; hs-CRP high-sensitivity C-reactive protein; HDL-cholesterol high-density lipoprotein cholesterol. 1 Cut-offs for tertiles 1–3 of serum uric acid levels are as follows: < 5.2, 5.2–6.1, and > 6.1 mg/dL in men and < 3.8, 3.8–4.4, and > 4.4 mg/dL in women, respectively. 2 Cut-offs for tertiles 1–3 of hs-CRP levels are as follows: < 0.45, 0.45–1.04, and > 1.04 mg/L in men and < 0.38, 0.38–0.89, and > 0.89 mg/L in women, respectively. Values are number (percentage) for categorical variables and mean ± standard deviation for continuous variables.
Table 2. Adjusted hazard ratios (with 95% confidence intervals) for type 2 diabetes according to serum uric acid levels in Korean adults aged 45–76 years. T tertile; HR hazard ratio; CI confidence interval. 1 Cut-offs for tertiles 1–3 of serum uric acid levels are as follows: < 5.2, 5.2–6.1, and > 6.1 mg/dL in men and < 3.8, 3.8–4.4, and > 4.4 mg/dL in women, respectively. 2 Hyperuricemia is defined as serum uric acid levels ≥ 7 mg/dL in men and ≥ 6 mg/dL in women. 3 Model 1: adjusted for sex (men or women) and age (years); Model 2: additionally adjusted for area of residence (Ansan or Ansung), education level (≤ elementary school, middle/high school, or ≥ college), smoking status (never, past, or current), alcohol consumption (g/d), regular physical activity (yes or no), body mass index (kg/m²), waist circumference (cm), systolic and diastolic blood pressure (mmHg), triglyceride (mg/dL), total cholesterol (mg/dL), high-density lipoprotein cholesterol (mg/dL) and fasting blood glucose level (mg/dL), and family history of diabetes (yes or no); Model 3: additionally adjusted for log-transformed hs-CRP levels.

| Tertile of serum uric acid¹ | HR (95% CI) | HR (95% CI) | HR (95% CI) | Per 1 log unit (mg/dL) incline in serum uric acid | Hyperuricemia (vs. non-hyperuricemia)² |
|----------------------------|-------------|-------------|-------------|---------------------------------|----------------------------------|
| T1 (lowest)                | HR (95% CI) | HR (95% CI) | HR (95% CI) | Per 1 log unit (mg/dL) incline in serum uric acid | HR (95% CI) |
| Total (n = 4152)           |             |             |             | Per 1 log unit (mg/dL) incline in serum uric acid | HR (95% CI) |
| Person-years               | 10,282      | 10,060      | 10,023      | 30,365                          | 2699                             |
| Incident cases (n)         | 127         | 152         | 269         | 548                             | 81                               |
| Rate per 1000 person-years | 12.4        | 15.1        | 26.8        | 18.0                            | 30.0                             |
| Model 1                    | 1.00        | 1.25 (0.99–1.59) | 2.22 (1.80–2.74) | < 0.0001                        | 3.15 (2.19–4.53) | 1.82 (1.43–2.31) |
| Model 2                    | 1.00        | 1.07 (0.84–1.36) | 1.63 (1.31–2.02) | < 0.0001                        | 1.47 (1.02–2.12) | 1.12 (0.87–1.44) |
| Model 3                    | 1.00        | 1.05 (0.83–1.33) | 1.54 (1.24–1.93) | < 0.0001                        | 1.47 (1.02–2.12) | 1.12 (0.87–1.44) |

Table 3. Adjusted hazard ratios (with 95% confidence intervals) for type 2 diabetes according to high-sensitivity C-reactive protein levels in Korean adults aged 45–76 years. T tertile; hs-CRP high-sensitivity C-reactive protein; HR hazard ratio; CI confidence interval. 1 Cut-offs for tertiles 1–3 of hs-CRP levels are as follows: < 0.45, 0.45–1.04, and > 1.04 mg/L in men and < 0.38, 0.38–0.89, and > 0.89 mg/L in women, respectively. 2 High inflammation is defined as > 2 mg/L of hs-CRP levels. 3 Model 1: adjusted for sex (men or women) and age (years); Model 2: additionally adjusted for area of residence (Ansan or Ansung), education level (≤ elementary school, middle/high school, or ≥ college), smoking status (never, past, or current), alcohol consumption (g/d), regular physical activity (yes or no), body mass index (kg/m²), waist circumference (cm), systolic and diastolic blood pressure (mmHg), triglyceride (mg/dL), total cholesterol (mg/dL), high-density lipoprotein cholesterol (mg/dL) and fasting blood glucose level (mg/dL), and family history of diabetes (yes or no); Model 3: additionally adjusted for log-transformed serum uric acid levels.

| Tertile of hs-CRP¹ | HR (95% CI) | HR (95% CI) | HR (95% CI) | Per 1 log unit (mg/L) incline in hs-CRP | High inflammation² (vs. low inflammation) |
|--------------------|-------------|-------------|-------------|---------------------------------|----------------------------------|
| T1 (lowest)        | HR (95% CI) | HR (95% CI) | HR (95% CI) | Per 1 log unit (mg/L) incline in hs-CRP | HR (95% CI) |
| Total (n = 4152)   |             |             |             | Per 1 log unit (mg/L) incline in hs-CRP | HR (95% CI) |
| Person-years       | 10,401      | 10,079      | 9,885       | 30,365                          | 3,760                             |
| Incident cases (n) | 98          | 184         | 255         | 548                             | 109                               |
| Rate per 1000 person-years | 9.4 | 18.3 | 25.8 | 18.0 | 29.0 |
| Model 1            | 1.00        | 1.81 (1.41–2.31) | 2.66 (2.11–3.36) | < 0.0001                        | 1.38 (1.27–1.50) | 1.68 (1.36–2.08) |
| Model 2            | 1.00        | 1.51 (1.17–1.94) | 1.96 (1.53–2.50) | < 0.0001                        | 1.19 (1.09–1.30) | 1.30 (1.05–1.61) |
| Model 3            | 1.00        | 1.48 (1.15–1.91) | 1.90 (1.48–2.43) | < 0.0001                        | 1.17 (1.07–1.29) | 1.27 (1.02–1.57) |

vs. Q1: 1.40; 95% CI: 1.02–1.92; P trend < 0.05. Along with a previous Chinese study, the present study found significant positive associations between serum uric acid levels and the incidence of T2DM, regardless of how we defined the exposure variable in the analytic models. Our findings reflect the robustness of these associations and suggest the potential role of elevated serum uric acid levels as an independent risk factor for T2DM among Korean adults.

As insulin resistance and T2DM may result from subclinical chronic low-grade inflammation, inflammatory cytokine levels have been reported to serve as effective biomarkers for T2DM. CRP is commonly used as a marker of systemic inflammation, and its association with T2DM has been evaluated in various non-diabetic populations. Some cross-sectional studies have shown that CRP levels vary substantially among different ethnic groups. Kelley et al. compared CRP levels among different ethnicities and reported that CRP concentrations were the highest among African Americans (median: 3.2 mg/L), followed by Hispanics (median: 2.3 mg/L), Caucasians (median: 1.5 mg/L), Chinese (median: 0.7 mg/L), and Japanese (median: 0.5 mg/L). In our study, the median hs-CRP level in Koreans was 0.6 mg/L, which was similar to than in other Asian groups and much lower than that in Westerners. Although differences in CRP distributions across populations have been acknowledged,
Several studies have shown a significant association between serum uric acid concentrations and the levels of CRP and pro-inflammatory markers involved in the causal pathways of T2DM. In observational studies, serum uric acid levels were positively associated with CRP levels\(^2,3\), TNF-\(\alpha\)\(^4\), and IL-6\(^5\). However, the underlying mechanisms by which uric acid increases the levels of inflammatory markers remain unclear. One possible explanation is that damaged cells and tissues release uric acid, which triggers inflammatory cytokines\(^6\). Results from an experimental study with human vascular and endothelial cells support the hypothesis that high serum uric acid concentrations stimulate CRP expression\(^7\). In contrast, pro-inflammatory cytokines play an important role in uric acid metabolism by upregulating the expression of xanthine oxidase\(^8\), which plays a key role in uric acid metabolism by converting xanthine to uric acid\(^9\). The increased expression of xanthine oxidase promotes the production of uric acid and superoxide free radicals\(^10\), resulting in endothelial dysfunction that may cause T2DM\(^11\). Therefore, studies exploring the role of the vicious cycle between uric acid and inflammation in the onset of metabolic disorders, including T2DM, are needed. However, to date, although the separate effects of serum uric acid and hs-CRP levels on the risk of T2DM have been recognized\(^12,13\), the combined effect of these two biomarkers on T2DM has not been investigated. Only a few cross-sectional studies have shown that the concurrent presence of elevated uric acid and CRP levels is associated with the risk of hypertension\(^14\), metabolic

| Tertile of serum uric acid\(^1\) | T1 (lowest) | T2 | T3 (highest) |
|---------------------------------|-------------|-----|--------------|
| HR (95% CI)\(^2\)              | 1.00        | 1.49 (0.87–2.55) | 2.79 (1.58–4.94) |
| HR (95% CI)                    | 1.90 (1.21–2.98)** | 2.00 (1.24–3.21)** | 3.69 (2.17–6.25)** |
| HR (95% CI)                    | 1.89 (1.20–2.98)** | 2.79 (1.75–4.46)** | 4.69 (2.81–7.84)** |

Table 4. Association of type 2 diabetes by serum uric acid and high-sensitivity C-reactive protein level strata in Korean adults aged 45–76 years. T tertile; hs-CRP, high-sensitivity C-reactive protein; HR, hazard ratio; CI, confidence interval. \(^1\)Cut-offs for tertiles 1–3 of serum uric acid levels are as follows: <5.2, 5.2–6.1, and >6.1 mg/dL in men and <3.8, 3.8–4.4, and >4.4 mg/dL in women, respectively. \(^2\)Cut-offs for tertiles 1–3 of hs-CRP levels are as follows: <0.45, 0.45–1.04, and >1.04 mg/L in men and <0.38, 0.38–0.89, and >0.89 mg/L in women, respectively. \(^*\)Individuals in the lowest tertile of serum uric acid and hs-CRP levels are used as the reference group. The model is adjusted for sex (men or women), age (years), area of residence (Ansan or Ansung), education level (≤elementary school, middle/high school, or ≥college), smoking status (never, past, or current), alcohol consumption (g/day), regular physical activity (yes or no), body mass index (kg/m\(^2\)), waist circumference (cm), systolic and diastolic blood pressure (mmHg), triglyceride (mg/dL), total cholesterol (mg/dL), high-density lipoprotein cholesterol (mg/dL) and fasting blood glucose level (mg/dL), and family history of diabetes (yes or no). \(^{**}\)P < 0.001.

| Model                           | AUC for the incidence of T2DM | Differentiate incidence |
|---------------------------------|-------------------------------|------------------------|
|                                 | 1-year | 5-year | 9-year | C-statistic\(^2\) | P\(^3\) | P\(^4\) | P\(^5\) |
| Conventional model\(^1\)        | 0.766  | 0.635  | 0.691  | 0.665             | Reference | –       | –       |
| + serum uric acid               | 0.921  | 0.720  | 0.747  | 0.748             | < 0.0001  | Reference | –       |
| + hs-CRP                        | 0.913  | 0.726  | 0.749  | 0.753             | < 0.0001  | 0.1366  | Reference |
| + serum uric acid and hs-CRP    | 0.930  | 0.731  | 0.754  | 0.758             | < 0.0001  | 0.0030  | 0.2445  |

Table 5. Overall ability of models predicting type 2 diabetes incidence in Korean adults aged 45–76 years. AUC area under the receiver operating characteristic curve; hs-CRP, high-sensitivity C-reactive protein; T2DM, type 2 diabetes mellitus. \(^1\)The conventional model is adjusted for sex (men or women), age (years), area of residence (Ansan or Ansung), education level (≤elementary school, middle/high school, or ≥college), smoking status (never, past, or current), alcohol consumption (g/day), regular physical activity (yes or no), body mass index (kg/m\(^2\)), waist circumference (cm), systolic and diastolic blood pressure (mmHg), triglyceride (mg/dL), total cholesterol (mg/dL), high-density lipoprotein cholesterol (mg/dL) and fasting blood glucose level (mg/dL), and family history of diabetes (yes or no). \(^2\)Uno’s C-statistic from Cox linear models. \(^3\)Compared with C-statistic of conventional model. \(^4\)Compared with C-statistic of + serum uric acid model. \(^5\)Compared with C-statistic of + hs-CRP model.
trained staff and interviewers using standardized protocols at baseline and subsequent follow-up examinations. In the Ansan–Ansan cohort study of the Korean Genome and Epidemiology Study (KoGES), in two Korean cities (Ansan and Ansan), 10,030 Korean adults aged between 40 and 69 years were recruited between 2001 and 2002 and followed up biennially. As previously described, data on sociodemographics, lifestyle, medical and medication history, and reproductive health were collected. Health examinations and blood and urine tests were performed by trained staff and interviewers using standardized protocols at baseline and subsequent follow-up examinations. In 2018, the Korea Center for Disease Control and Prevention (KCDC) newly released data on the levels of 15 biomarkers, including serum uric acid, from stored serum samples collected at the 3rd follow-up examination between 2007 and 2008. Therefore, in this study, data from the 3rd follow-up examination were considered as the baseline to include data on serum uric acid levels. From a total of 6688 participants who completed the 3rd follow-up examination (2007–2008), 1,110 were excluded because stored serum samples were not available. We further excluded participants with T2DM (n = 1252), any type of cancer (n = 64), or gout (n = 6). Of these, 37 participants were not suitable for the current study because of missing information on covariates. To rule out confounding by acute infection, participants with hs-CRP levels of > 10 mg/L were excluded from the final analysis (n = 67). Finally, 4152 Korean adults (1875 men and 2277 women) who were followed-up until 2016 were included in this study (Fig. 1). The KoGES study was reviewed and approved by the Institutional Review Board of the Korea Centers for Disease Control and Prevention, and written informed consent was obtained from all the participants. All methods were performed in compliance with relevant institutional guidelines and regulations. The protocol was reviewed and approved by the Institutional Review Board of Korea National University of Education on November 24, 2020 (IRB No. KNUE-202011-BMBR-0102-01).

Assessment of serum uric acid and hs-CRP. Blood samples for the laboratory tests were collected after overnight fasting. Serum uric acid and hs-CRP concentrations were assessed using enzymatic colorimetric methods with an automatic analyzer (ADVIA 1650 and 1800, Siemens, Tarrytown, NY, USA). Serum uric acid and hs-CRP levels, the main exposure variables of interest, were analyzed as tertiles based on sex-specific distributions and as continuous measures. Both exposure variables were analyzed as dichotomous variables. For dichotomous analyses, hyperuricemia was defined as serum uric acid levels ≥ 7 mg/dL in men and ≥ 6 mg/dL in women. This is the saturation point of monosodium urate, which is the prevalent form of uric acid in extracellular fluids. High inflammation was defined as hs-CRP levels > 2 mg/L in both men and women, as previously used in the Asian population.

Ascertainment of T2DM. The incidence of T2DM was determined if participants had fasting blood glucose levels ≥ 126 mg/dL or 2-h oral glucose tolerance tests (OGTT) ≥ 200 mg/dL at follow-up examinations, based on the World Health Organization and American Diabetes Association. In addition, participants who were newly diagnosed with T2DM after the previous examination or who used insulin or oral anti-diabetic medicine were considered T2DM cases.

Conclusions
In summary, elevated levels of serum uric acid and hs-CRP were independently associated with an increased incidence of T2DM. Although there was no significant synergistic effect of these two indicators, the concurrent presence of elevated serum uric acid and hs-CRP levels may exacerbate the risk of T2DM development in a large Korean cohort aged 45 years and older. Our findings suggest that monitoring serum uric acid and hs-CRP levels can be an effective strategy for identifying individuals at high risk of T2DM development among Korean adults.
Statistical analyses. Differences in the general characteristics of study participants across the categories of serum uric acid and hs-CRP levels were tested using the Mantel–Haenszel chi-square test for categorical variables and generalized linear regression for continuous variables, respectively. Data for serum uric acid and hs-CRP levels were right-skewed and log-transformed before the analysis.

Multivariable Cox proportional hazard models were used to estimate the future risk of T2DM development. To test for linear trends, we used the median of each tertile of serum uric acid and hs-CRP levels as continuous variables. The following covariates were used for adjustment: sex (men or women) and age (years) were adjusted in Model 1; area of residence (Ansan or Ansung), education level (≤ elementary school, middle/high school, or ≥ college), smoking status (never, past, or current), alcohol consumption (g/d), regular physical activity (yes or no), BMI (kg/m²), WC (cm), systolic and diastolic blood pressure (mmHg), triglyceride (mg/dL), total cholesterol (mg/dL), HDL-cholesterol (mg/dL), fasting blood glucose (mg/dL), and family history of diabetes (yes or no) were additionally adjusted in Model 2; log-transformed serum uric acid or hs-CRP levels were additionally adjusted in Model 3. To explore the combined effect of serum uric acid and hs-CRP levels on the incidence of T2DM, we cross-classified participants according to tertiles of serum uric acid and hs-CRP levels and analyzed the interactions between serum uric acid and hs-CRP levels and the incidence of T2DM. To test for potential interactions between serum uric acid and hs-CRP levels, we applied multiplicative interaction by including corresponding interaction terms (serum uric acid level × serum hs-CRP level, treated as log-transformed continuous variables) in the fully adjusted models. The lowest tertile of both variables was used as the reference. Uno’s C-statistics from the Cox models were used to assess the differences in the overall prediction ability among the T2DM incidence predictive models. The conventional prediction model included established T2DM risk factors such as sex, age, residential area, education level, smoking status, alcohol consumption, regular
physical activity, BMI, WC, systolic and diastolic blood pressure, triglyceride, total cholesterol, HDL-cholesterol, fasting glucose levels, and family history of diabetes. In the other three prediction models, serum uric acid and hs-CRP levels were additionally included individually or together, and the predictive abilities of the three models were compared with the conventional model.

SAS version 9.4 (SAS Institute, Cary, NC, USA) was used for all statistical analyses. Statistical tests were two-sided, and a P value < 0.05 was considered significant.

Received: 14 December 2021; Accepted: 20 June 2022
Published online: 29 June 2022

References

1. Roth, G. A. et al. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet 392, 1736–1788 (2018).
2. International Diabetes Federation. IDF Diabetes Atlas 8th edition (2017).
3. Litwak, L. et al. Prevalence of diabetes complications in people with type 2 diabetes mellitus and its association with baseline characteristics in the multinational AChieve study. Diabetol. Metab. Syndr. 5, 57 (2013).
4. Pepys, M. B. & Baltz, M. L. Acute phase proteins with special reference to C-reactive protein and related proteins (pentaxins) and serum amyloid A protein. Adv. Immunol. 34, 141–212 (1983).
5. Liu, C. et al. Adiponectin, TNF-α and inflammatory cytokines and risk of type 2 diabetes: A systematic review and meta-analysis. Cytokine 86, 100–109 (2016).
6. Kelley-Hedgepeth, A. et al. Ethnic differences in C-reactive protein concentrations. Clin. Chem. 54, 1027–1037 (2008).
7. Mandal, A. K. & Mount, D. B. The molecular physiology of uric acid homeostasis. Annu. Rev. Physiol. 77, 323–345 (2015).
8. Dehghan, A., Van Hoek, M., Sjöbrands, E. J., Hofman, A. & Witteman, J. C. High serum uric acid as a novel risk factor for type 2 diabetes. Diabetes Care 31, 361–362 (2008).
9. Bhole, V. et al. Serum uric acid levels and the risk of type 2 diabetes: A prospective study. Am. J. Med. 123, 957–961 (2010).
10. Nakagawa, T., Tuttle, K. R., Short, R. A. & Johnson, R. J. Hypothesis: Fructose-induced hyperuricemia as a causal mechanism for the epidemic of the metabolic syndrome. Nat. Clin. Pract. Nephrol. 1, 80–86 (2005).
11. Kanellis, J. & Kang, D. H. Uric acid as a mediator of endothelial dysfunction, inflammation, and vascular disease. Semin. Nephrol. 35, 39–42 (2005).
12. Khosla, U. M. et al. Hyperuricemia induces endothelial dysfunction. Kidney Int. 67, 1739–1742 (2005).
13. Ruggiero, C. et al. Uric acid and inflammatory markers. Eur. Heart J. 27, 1174–1181 (2006).
14. Kushiyama, A. et al. Role of uric acid metabolism-related inflammation in the pathogenesis of metabolic syndrome components such as atherosclerosis and nonalcoholic steatohepatitis. Med. Inflamm. 2016, 8603164 (2016).
15. Komaki, Y. et al. Cytokine-mediated xanthine oxidase upregulation in chronic obstructive pulmonary disease's airways. Pulm. Pharmacol. Ther. 18, 297–302 (2005).
16. Taniguchi, Y. et al. Serum uric acid and the risk for hypertension and type 2 diabetes in Japanese men: The Osaka Health Survey. J. Hypertens. 19, 1209–1215 (2001).
17. Chien, K. L. et al. Plasma uric acid and the risk of type 2 diabetes in a Chinese community. Clin. Chem. 54, 310–318 (2008).
18. Galie, M. & Fernandez, M. Inflammation and type 2 diabetes. Diabetes Metab. 38, 183–191 (2012).
19. Khera, A. et al. Race and gender differences in C-reactive protein levels. J. Am. Coll. Cardiol. 46, 464–469 (2005).
20. Pan, A., Wang, Y., Yuan, J. & Koh, W. High-sensitive C-reactive protein and risk of incident type 2 diabetes: A case–control study nested within the Singapore Chinese Health Study. BMC Endocr. Disord. 17, 8 (2017).
21. Nakashishy, S., Yaman, K., Kamei, N., Okubo, M. & Kohno, N. Elevated C-reactive protein is a risk factor for the development of type 2 diabetes in Japanese Americans. Diabetes Care 26, 2754–2757 (2003).
22. Coutinho, T. A. et al. Associations of serum uric acid with markers of inflammation, metabolic syndrome, and subclinical coronary atherosclerosis. Am. J. Hypertens. 20, 83–89 (2007).
23. Lyngdoh, T. et al. Elevated serum uric acid is associated with high circulating inflammatory cytokines in the population-based Colaus study. PLoS ONE 6, e19901 (2011).
24. Kono, H., Chen, C. J., Ontiveros, F. & Rock, K. L. Uric acid promotes an acute inflammatory response to sterile cell death in mice. J. Clin. Invest. 120, 1939–1949 (2010).
25. Mauolo, I., Oppedisano, F., Grafteri, S., Muscoli, C. & Mollace, V. Regulation of uric acid metabolism and excretion. Int. J. Cardiol. 213, 8–14 (2016).
26. Pradhan, A. D., Manson, J. E., Rifai, N., Buring, J. E. & Ridker, P. M. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 286, 327–334 (2001).
27. Krishnan, E., Pandya, B. J., Chung, L., Hariri, A. & Dabbous, O. Hyperuricemia in young adults and risk of insulin resistance, prediabetes, and diabetes: A 15-year follow-up study. Am. J. Epidemiol. 2012(176), 108–116 (2012).
28. Krishnan, E. Interaction of inflammation, hyperuricemia, and the prevalence of hypertension among adults free of metabolic syndrome: NHANES 2009–2010. J. Am. Heart Assoc. 3, e00157 (2014).
29. Kawamoto, R. et al. Usefulness of combining serum uric acid and high-sensitivity C-reactive protein for risk stratification of patients with metabolic syndrome in community-dwelling women. Endocrine 44, 132–139 (2013).
30. Park, C. E. et al. Gender difference in the relationship between uric acid and pulse pressure among Korean adults. Clin. Exp. Hypertens. 41, 499–504 (2018).
31. Song, B. et al. Association between C reactive protein level and depressive symptoms in an elderly Korean population: Korean Social Life, Health and Aging Project. BMJ Open S, e006429 (2015).
32. Kim, Y., Han, B. G. & KoGES group. Cohort profile: The Korean genome and epidemiology study (KoGES) Consortium. Int. J. Epidemiol. 46, e20 (2017).
33. Desai, R. V. et al. Effect of serum insulin on the association between hyperuricemia and incident heart failure. Am. J. Cardiol. 106, 1134–1138 (2010).
34. Loeb, J. N. The influence of temperature on the solubility of monosodium urate. Arthritis Rheum. 15, 189–192 (1972).
35. Thompson, A. L. et al. Weight gain trajectories associated with elevated C-reactive protein levels in Chinese adults. J. Am. Heart Assoc. 5, e003262 (2016).
36. World Health Organization. Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia: Report of a WHO/IDF consultation (2006).
37. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 37, S81–S90 (2014).
Acknowledgements
This study was conducted with bioresources from the National Biobank of Korea, the Centers for Disease Control and Prevention, Republic of Korea (KBN-2020-014).

Author contributions
K.W.L. conceptualized the study design, conducted statistical analyses, interpreted data, wrote the first draft of the manuscript, and revised the manuscript. D.S. conceptualized the study, conducted statistical analyses, interpreted data, supervised all aspects of implementation, and revised the manuscript. All authors have reviewed and approved the final version of the manuscript for publication.

Funding
This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIT) (Grant no. 2020R1G1A1100454).

Competing interests
The authors declare no competing interests.

Additional information
Correspondence and requests for materials should be addressed to D.S.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022